- Haemonetics Corporation recently received U.S. Food and Drug Administration approval to expand labeling for its VASCADE MVP XL venous vascular closure system to cover larger 10–14F inner diameter and up to 17F outer diameter procedural sheaths used in pulsed field ablation and left atrial appendage closure for atrial fibrillation.
- This decision, backed by the AMBULATE EXPAND trial showing no major or minor access site closure-related complications and rapid ambulation, strengthens Haemonetics’ position in advanced electrophysiology procedures as the only extravascular venous closure system clinically proven for use with up to 17F outer diameter sheaths.
- We will now examine how FDA-backed expansion of VASCADE MVP XL into larger-sheath electrophysiology procedures could influence Haemonetics’ broader investment narrative.
We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Haemonetics Investment Narrative Recap
To own Haemonetics, you need to believe its core platforms in plasma, hemostasis and interventional technologies can remain relevant while execution in VASCADE improves. The VASCADE MVP XL label expansion directly targets one of the key near term catalysts: restoring momentum in electrophysiology. It modestly reduces the risk that VASCADE underperformance persists, although competitive pressure and reliance on a few U.S. centric franchises remain central concerns.
Among recent announcements, the FDA clearance of the NexSys PCS system with Persona PLUS stands out alongside VASCADE MVP XL. Together, they highlight Haemonetics’ focus on enhancing core platforms rather than broad diversification. For investors watching catalysts, NexSys and VASCADE now both have fresh regulatory support, but that does not eliminate the risk that competition, pricing pressure or operational issues could still weigh on growth and margins.
However, investors should also be aware that persistent competition in vascular closure and underperforming electrophysiology volumes could still...
Read the full narrative on Haemonetics (it's free!)
Haemonetics' narrative projects $1.5 billion revenue and $257.9 million earnings by 2028. This requires 2.6% yearly revenue growth and an earnings increase of about $94.6 million from $163.3 million today.
Uncover how Haemonetics' forecasts yield a $88.00 fair value, a 60% upside to its current price.
Exploring Other Perspectives
Some of the lowest estimate analysts took a far more cautious view, assuming revenue of about US$1.5 billion and earnings near US$247 million by 2029, so this new VASCADE approval may prompt you to reassess whether those conservative expectations around electrophysiology competition still make sense.
Explore 2 other fair value estimates on Haemonetics - why the stock might be worth as much as 67% more than the current price!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Haemonetics research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Haemonetics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Haemonetics' overall financial health at a glance.
Contemplating Other Strategies?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Find 63 companies with promising cash flow potential yet trading below their fair value.
- Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com